Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
NCT ID: NCT06820957
Last Updated: 2025-11-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2/PHASE3
Total Enrollment
437 participants
Study Classification
INTERVENTIONAL
Study Start Date
2026-07-17
Study Completion Date
2032-07-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase II/III trial compares the effect of vincristine, irinotecan, and regorafenib (VIrR) in combination with vincristine, doxorubicin, cyclophosphamide (VDC), ifosfamide and etoposide (IE) to usual treatment with VDC/IE for the treatment of newly diagnosed Ewing sarcoma or other round cell sarcomas that have spread from where they first started (primary site) to other places in the body (metastatic). Vincristine is in a class of medications called vinca alkaloids. It works by stopping tumor cells from growing and dividing and may kill them. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and deoxyribonucleic acid (DNA) repair and may kill tumor cells. Regorafenib, a type of kinase inhibitor and a type of antiangiogenesis agent, blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells. It may also lower the body's immune response. Ifosfamide, a type of alkylating agent and a type of antimetabolite, attaches to DNA in cells and may kill tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Giving VIrR/VDC/IE may be more effective than usual treatment with VDC/IE in treating patients with newly diagnosed metastatic Ewing sarcoma or other round cell sarcomas.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVE:
I. To determine if the event-free survival (EFS) in patients with newly diagnosed metastatic Ewing sarcoma is improved when treated with vincristine-irinotecan-regorafenib (VIrR) after initial treatment with vincristine-doxorubicin-cyclophosphamide (VDC) and ifosfamide-etoposide (IE) compared to patients treated with 17 cycles of interval compressed VDC and IE chemotherapy.
SECONDARY OBJECTIVES:
I. To compare the overall survival (OS) of patients with newly diagnosed metastatic Ewing sarcoma treated with VDC/IE/VIrR versus VDC/IE.
II. To compare the toxicity profile of VDC/IE/VIrR to VDC/IE in patients with newly diagnosed metastatic Ewing sarcoma, using both investigator-reported and patient-reported Common Terminology Criteria for Adverse Events (CTCAE).
III. To describe the feasibility and toxicity of augmented dose radiotherapy with 64.8 Gy as local control for patients with newly diagnosed metastatic Ewing sarcoma with large primary tumors.
IV. To prospectively validate that circulating tumor-derived DNA (ctDNA) levels greater than or equal to 5% at the time of diagnosis are associated with increased risk of EFS-event for patients with newly diagnosed metastatic Ewing sarcoma.
V. To prospectively validate that elevated ctDNA levels greater than or equal to 0.5% burden following one cycle of chemotherapy are associated with increased risk of EFS-event for patients with newly diagnosed metastatic Ewing sarcoma.
EXPLORATORY OBJECTIVES:
I. To estimate 1- and 2-year EFS and response rate for patients with newly diagnosed, eligible metastatic round cell sarcomas other than Ewing sarcoma.
II. To characterize the change in fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) imaging response of primary disease site at the end of Induction chemotherapy and its association with EFS.
III. To explore distinguishing histologic attributes of Ewing sarcoma and round cell sarcomas that mimic Ewing sarcoma.
IV. To collect bone marrow and tissue samples to bank for future research. V. To explore other ctDNA predictor variables, time points, and potential association with EFS in patients with newly diagnosed metastatic Ewing sarcoma.
VI. To estimate the frequency of selected toxicities by Patient Reported Outcomes (PRO)-CTCAE and symptom bother by Functional Assessment of Cancer Therapy General Questionnaire (FACT-G) and to evaluate if these findings are associated with duration of protocol therapy and treatment arm.
OUTLINE:
INDUCTION: Patients receive vincristine intravenously (IV) on days 1 and 8, doxorubicin IV over 3-15 minutes on days 1 and 2, and cyclophosphamide IV over 30-60 minutes on day 1 of cycles 1, 3 and 5. Patients also receive ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 of cycles 2, 4 and 6. Cycles repeat every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery or radiation therapy per investigator choice.
CONSOLIDATION I: Patients receive vincristine IV on days 1 and 8, doxorubicin IV over 3-15 minutes on days 1 and 2, and cyclophosphamide IV over 30-60 minutes on day 1 of cycles 1 and 2. Patients also receive ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 of cycles 3 and 4. Cycles repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION II: After 10 cycles of therapy, patients with Ewing Sarcoma are randomized to 1 of 2 regimens. Patients with a diagnosis of other eligible metastatic round cell sarcomas are assigned to Regimen A.
REGIMEN A: Patients receive vincristine IV on days 1 and 8 and cyclophosphamide IV over 30-60 minutes on day 1 of cycles 1, 3, 5 and 7. Patients also receive ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 of cycles 2, 4 and 6. Cycles repeat every 14 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. After systemic therapy completed, patients undergo metastatic site radiation therapy.
REGIMEN B: Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 90 minutes on days 1-5 of each cycle. Patients also receive regorafenib orally (PO) on days 8-14 or 15-21 of cycle 1, and then on days 8-21 of cycles thereafter. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. After systemic therapy completed, patients undergo metastatic site radiation therapy.
Additionally, patients undergo blood sample collection, echocardiography, magnetic resonance imaging (MRI), computed tomography (CT), chest CT, and/or FDG-PET throughout the study. Patients may also undergo optional collection of tumor tissue and/or bone marrow aspiration and biopsy on study.
After completion of study treatment, patients are followed every 3 months for years 1 and 2, every 6 months for years 3 and 4 then every 12 months for years 5-10.
I. To determine if the event-free survival (EFS) in patients with newly diagnosed metastatic Ewing sarcoma is improved when treated with vincristine-irinotecan-regorafenib (VIrR) after initial treatment with vincristine-doxorubicin-cyclophosphamide (VDC) and ifosfamide-etoposide (IE) compared to patients treated with 17 cycles of interval compressed VDC and IE chemotherapy.
SECONDARY OBJECTIVES:
I. To compare the overall survival (OS) of patients with newly diagnosed metastatic Ewing sarcoma treated with VDC/IE/VIrR versus VDC/IE.
II. To compare the toxicity profile of VDC/IE/VIrR to VDC/IE in patients with newly diagnosed metastatic Ewing sarcoma, using both investigator-reported and patient-reported Common Terminology Criteria for Adverse Events (CTCAE).
III. To describe the feasibility and toxicity of augmented dose radiotherapy with 64.8 Gy as local control for patients with newly diagnosed metastatic Ewing sarcoma with large primary tumors.
IV. To prospectively validate that circulating tumor-derived DNA (ctDNA) levels greater than or equal to 5% at the time of diagnosis are associated with increased risk of EFS-event for patients with newly diagnosed metastatic Ewing sarcoma.
V. To prospectively validate that elevated ctDNA levels greater than or equal to 0.5% burden following one cycle of chemotherapy are associated with increased risk of EFS-event for patients with newly diagnosed metastatic Ewing sarcoma.
EXPLORATORY OBJECTIVES:
I. To estimate 1- and 2-year EFS and response rate for patients with newly diagnosed, eligible metastatic round cell sarcomas other than Ewing sarcoma.
II. To characterize the change in fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) imaging response of primary disease site at the end of Induction chemotherapy and its association with EFS.
III. To explore distinguishing histologic attributes of Ewing sarcoma and round cell sarcomas that mimic Ewing sarcoma.
IV. To collect bone marrow and tissue samples to bank for future research. V. To explore other ctDNA predictor variables, time points, and potential association with EFS in patients with newly diagnosed metastatic Ewing sarcoma.
VI. To estimate the frequency of selected toxicities by Patient Reported Outcomes (PRO)-CTCAE and symptom bother by Functional Assessment of Cancer Therapy General Questionnaire (FACT-G) and to evaluate if these findings are associated with duration of protocol therapy and treatment arm.
OUTLINE:
INDUCTION: Patients receive vincristine intravenously (IV) on days 1 and 8, doxorubicin IV over 3-15 minutes on days 1 and 2, and cyclophosphamide IV over 30-60 minutes on day 1 of cycles 1, 3 and 5. Patients also receive ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 of cycles 2, 4 and 6. Cycles repeat every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery or radiation therapy per investigator choice.
CONSOLIDATION I: Patients receive vincristine IV on days 1 and 8, doxorubicin IV over 3-15 minutes on days 1 and 2, and cyclophosphamide IV over 30-60 minutes on day 1 of cycles 1 and 2. Patients also receive ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 of cycles 3 and 4. Cycles repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION II: After 10 cycles of therapy, patients with Ewing Sarcoma are randomized to 1 of 2 regimens. Patients with a diagnosis of other eligible metastatic round cell sarcomas are assigned to Regimen A.
REGIMEN A: Patients receive vincristine IV on days 1 and 8 and cyclophosphamide IV over 30-60 minutes on day 1 of cycles 1, 3, 5 and 7. Patients also receive ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 of cycles 2, 4 and 6. Cycles repeat every 14 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. After systemic therapy completed, patients undergo metastatic site radiation therapy.
REGIMEN B: Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 90 minutes on days 1-5 of each cycle. Patients also receive regorafenib orally (PO) on days 8-14 or 15-21 of cycle 1, and then on days 8-21 of cycles thereafter. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. After systemic therapy completed, patients undergo metastatic site radiation therapy.
Additionally, patients undergo blood sample collection, echocardiography, magnetic resonance imaging (MRI), computed tomography (CT), chest CT, and/or FDG-PET throughout the study. Patients may also undergo optional collection of tumor tissue and/or bone marrow aspiration and biopsy on study.
After completion of study treatment, patients are followed every 3 months for years 1 and 2, every 6 months for years 3 and 4 then every 12 months for years 5-10.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
CIC-Rearranged Sarcoma
Metastatic Ewing Sarcoma
Metastatic High Grade Sarcoma
Metastatic Undifferentiated Round Cell Sarcoma
Metastatic Undifferentiated Sarcoma, Not Otherwise Specified
Round Cell Sarcoma With EWSR1-non-ETS Fusion
Sarcoma With BCOR Genetic Alterations
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Regimen A (VDC/IE)
See Detailed description
Group Type
ACTIVE_COMPARATOR
Biopsy Procedure
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Biospecimen Collection
Intervention Type
PROCEDURE
Undergo tissue and/or blood sample collection
Bone Marrow Aspiration
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Bone Marrow Biopsy
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Computed Tomography
Intervention Type
PROCEDURE
Undergo CT
Cyclophosphamide
Intervention Type
DRUG
Given IV
Doxorubicin Hydrochloride
Intervention Type
DRUG
Given IV
Echocardiography Test
Intervention Type
PROCEDURE
Undergo echocardiography
Etoposide
Intervention Type
DRUG
Given IV
Fludeoxyglucose F-18
Intervention Type
OTHER
Given FDG
Ifosfamide
Intervention Type
DRUG
Given IV
Magnetic Resonance Imaging
Intervention Type
PROCEDURE
Undergo MRI
Positron Emission Tomography
Intervention Type
PROCEDURE
Undergo FDG PET
Questionnaire Administration
Intervention Type
OTHER
Ancillary studies
Radiation Therapy
Intervention Type
RADIATION
Undergo radiation
Surgical Procedure
Intervention Type
PROCEDURE
Undergo surgery
Vincristine Sulfate
Intervention Type
DRUG
Given IV
Regimen B (VIrR/VDC/IE)
See Detailed Description
Group Type
EXPERIMENTAL
Biopsy Procedure
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Biospecimen Collection
Intervention Type
PROCEDURE
Undergo tissue and/or blood sample collection
Bone Marrow Aspiration
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Bone Marrow Biopsy
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Computed Tomography
Intervention Type
PROCEDURE
Undergo CT
Cyclophosphamide
Intervention Type
DRUG
Given IV
Doxorubicin Hydrochloride
Intervention Type
DRUG
Given IV
Echocardiography Test
Intervention Type
PROCEDURE
Undergo echocardiography
Etoposide
Intervention Type
DRUG
Given IV
Fludeoxyglucose F-18
Intervention Type
OTHER
Given FDG
Ifosfamide
Intervention Type
DRUG
Given IV
Irinotecan Hydrochloride
Intervention Type
DRUG
Given IV
Magnetic Resonance Imaging
Intervention Type
PROCEDURE
Undergo MRI
Positron Emission Tomography
Intervention Type
PROCEDURE
Undergo FDG PET
Questionnaire Administration
Intervention Type
OTHER
Ancillary studies
Radiation Therapy
Intervention Type
RADIATION
Undergo radiation
Regorafenib
Intervention Type
DRUG
Given PO
Surgical Procedure
Intervention Type
PROCEDURE
Undergo surgery
Vincristine Sulfate
Intervention Type
DRUG
Given IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biopsy Procedure
Undergo bone marrow aspiration and biopsy
Intervention Type
PROCEDURE
Biospecimen Collection
Undergo tissue and/or blood sample collection
Intervention Type
PROCEDURE
Bone Marrow Aspiration
Undergo bone marrow aspiration and biopsy
Intervention Type
PROCEDURE
Bone Marrow Biopsy
Undergo bone marrow aspiration and biopsy
Intervention Type
PROCEDURE
Computed Tomography
Undergo CT
Intervention Type
PROCEDURE
Cyclophosphamide
Given IV
Intervention Type
DRUG
Doxorubicin Hydrochloride
Given IV
Intervention Type
DRUG
Echocardiography Test
Undergo echocardiography
Intervention Type
PROCEDURE
Etoposide
Given IV
Intervention Type
DRUG
Fludeoxyglucose F-18
Given FDG
Intervention Type
OTHER
Ifosfamide
Given IV
Intervention Type
DRUG
Irinotecan Hydrochloride
Given IV
Intervention Type
DRUG
Magnetic Resonance Imaging
Undergo MRI
Intervention Type
PROCEDURE
Positron Emission Tomography
Undergo FDG PET
Intervention Type
PROCEDURE
Questionnaire Administration
Ancillary studies
Intervention Type
OTHER
Radiation Therapy
Undergo radiation
Intervention Type
RADIATION
Regorafenib
Given PO
Intervention Type
DRUG
Surgical Procedure
Undergo surgery
Intervention Type
PROCEDURE
Vincristine Sulfate
Given IV
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Biopsy
BIOPSY_TYPE
Bx
Biological Sample Collection
Biospecimen Collected
Specimen Collection
Biopsy of Bone Marrow
Biopsy, Bone Marrow
CAT
CAT Scan
Computed Axial Tomography
Computerized Axial Tomography
Computerized axial tomography (procedure)
Computerized Tomography
Computerized Tomography (CT) scan
CT
CT Scan
Diagnostic CAT Scan
Diagnostic CAT Scan Service Type
tomography
(-)-Cyclophosphamide
2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
Asta B 518
B 518
B-518
B518
Carloxan
Ciclofosfamida
Ciclofosfamide
Cicloxal
Clafen
Claphene
CP monohydrate
CTX
CYCLO-cell
Cycloblastin
Cycloblastine
Cyclophospham
Cyclophosphamid monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclostin
Cyclostine
Cytophosphan
Cytophosphane
Cytoxan
Fosfaseron
Genoxal
Genuxal
Ledoxina
Mitoxan
Neosar
Revimmune
Syklofosfamid
WR 138719
WR- 138719
WR-138719
WR138719
5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)
ADM
Adriacin
Adriamycin
Adriamycin Hydrochloride
Adriamycin PFS
Adriamycin RDF
ADRIAMYCIN, HYDROCHLORIDE
Adriamycine
Adriblastina
Adriblastine
Adrimedac
Chloridrato de Doxorrubicina
DOX
DOXO-CELL
Doxolem
Doxorubicin HCl
Doxorubicin.HCl
Doxorubin
Farmiblastina
FI 106
FI-106
FI106
hydroxydaunorubicin
Rubex
EC
Echocardiography
Demethyl Epipodophyllotoxin Ethylidine Glucoside
EPEG
Lastet
Toposar
Vepesid
VP 16
VP 16-213
VP 16213
VP-16
VP-16-213
VP-16213
VP16
VP16213
18FDG
FDG
Fludeoxyglucose (18F)
fludeoxyglucose F 18
Fludeoxyglucose F18
Fluorine-18 2-Fluoro-2-deoxy-D-Glucose
Fluorodeoxyglucose F18
Asta Z 4942
Asta Z-4942
Cyfos
Holoxan
Holoxane
Ifex
IFO
IFO-Cell
Ifolem
Ifomida
Ifomide
Ifosfamidum
Ifoxan
IFX
Iphosphamid
Iphosphamide
Iso-Endoxan
Isoendoxan
Isophosphamide
Mitoxana
MJF 9325
MJF-9325
Naxamide
Seromida
Tronoxal
Z 4942
Z-4942
Campto
Camptosar
Camptothecin 11
Camptothecin-11
CPT 11
CPT-11
CPT11
Irinomedac
Irinotecan Hydrochloride Trihydrate
Irinotecan Monohydrochloride Trihydrate
U 101440E
U-101440E
U101440E
Magnetic Resonance
Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (procedure)
Magnetic Resonance Imaging Scan
Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
MR
MR Imaging
MRI
MRI Scan
MRIs
NMR Imaging
NMRI
Nuclear Magnetic Resonance Imaging
sMRI
Structural MRI
Medical Imaging, Positron Emission Tomography
PET
PET Scan
Positron emission tomography (procedure)
Positron Emission Tomography Scan
Positron-Emission Tomography
PT
Cancer Radiotherapy
Energy Type
ENERGY_TYPE
Irradiate
Irradiated
Irradiation
Radiation
Radiation Therapy, NOS
Radiotherapeutics
Radiotherapy
RT
Therapy, Radiation
BAY 73-4506 Monohydrate
BAY-73-4506 Monohydrate
Regorafenib Monohydrate
Stivarga
Operation
Surgery
Surgery Type
Surgery, NOS
Surgical
Surgical Intervention
Surgical Interventions
Surgical Procedures
Type of Surgery
Kyocristine
Leurocristine Sulfate
Leurocristine, sulfate
Oncovin
Vincasar
Vincosid
Vincrex
Vincristine, sulfate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All patients must be enrolled on APEC14B1 and consented to the Molecular Characterization Initiative (Part A) prior to enrollment and treatment on AEWS2431
* Patients must be ≥ 12 months to ≤ 50 years of age at time of enrollment
* Newly diagnosed Ewing sarcoma and other round cell sarcomas as follows. For the purposes of eligibility, the following pathology diagnoses are eligible and molecular confirmation is not required to enroll:
* Histologically confirmed Ewing sarcoma
* Suspected Ewing sarcoma with molecular confirmation pending
* Suspected high grade round cell sarcomas/sarcomas with eligible molecular alterations, pending molecular confirmation
* Round cell sarcoma consistent with Ewing sarcoma
* Round cell sarcoma not otherwise specified
* Round cell sarcoma
* Round cell sarcomas with EWSR1-non-ETS fusion
* CIC-rearranged sarcoma
* Sarcoma with BCOR genetic alterations
* Patients with the following pathologic diagnoses that are known to contain EWSR1 or FUS fusions are not eligible:
* Angiomatoid fibrous histiocytoma
* Extraskeletal myxoid chondrosarcoma
* Desmoplastic small round cell tumor
* Clear cell sarcoma
* Myxoid liposarcoma
* If clinical molecular testing that reports both fusion partners has been successfully completed by the site prior to enrollment, patients may only enroll if that testing reported one of the eligible fusions
* All patients must have evidence of distant metastatic disease. Biopsy of metastatic sites is not required. For this study, distant metastatic disease is defined as one or more of the following:
* Lesions which are discontinuous from the primary tumor, are not regional lymph nodes, and do not share a bone or body cavity with the primary tumor. Skip lesions in the same bone as the primary tumor do not constitute metastatic disease. Skip lesions in an adjacent bone are considered bone metastasis. If there is any doubt whether lesions are metastatic, a biopsy of those lesions should be performed
* Contralateral pleural effusion and/or contralateral pleural nodules
* Distant lymph node involvement
* Patients with pulmonary nodules are considered to have metastatic disease if the patient has:
* Solitary nodule ≥ 0.5 cm or multiple nodules of ≥ 0.3 cm unless lesion is biopsied and negative for tumor
* Patients with solitary nodule \< 0.5 cm or multiple nodules \< 0.3 cm are not considered to have lung metastasis unless biopsy documents tumor
* Bone marrow metastatic disease (bone marrow disease) is based on morphologic evidence of Ewing sarcoma based on hematoxylin and eosin (H\&E) stains. In the absence of morphologic evidence of marrow involvement on H\&E, patients with bone marrow involvement detected ONLY by flow cytometry, reverse transcriptase-polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH), immunohistochemistry or PET-CT will NOT be considered to have clinical bone marrow involvement for the purposes of this study
* Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 50 mL/min/1.73 m\^2 or serum creatinine based on age/sex as follows:
* Age: 1 to \< 2 years: Male 0.6; female 0.6
* Age: 2 to \< 6 years: Male 0.8; female 0.8
* Age: 6 to \< 10 years: Male 1; female 1
* Age: 10 to \< 13 years: Male 1.2; female 1.2
* Age: 13 to \< 16 years: Male 1.5; female 1.4
* Age: ≥ 16 years: Male 1.7; female 1.4 OR
* A 24-hour urine creatinine clearance ≥ 50 mL/min/1.73 m\^2 OR
* A GFR ≥ 50 mL/min/1.73 m\^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard)
* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age
* Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase \[ALT\]) ≤ 3 x ULN for age (except for patients with liver metastasis who may enroll if ALT ≤ 5 times ULN for age)
* Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
* Shortening fraction of ≥ 27% by echocardiogram, or ejection fraction of ≥ 50% by echocardiogram
* No known congenital QT syndrome
* No known family history of congenital QT syndrome
* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better
* Known HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
* Patients must be ≥ 12 months to ≤ 50 years of age at time of enrollment
* Newly diagnosed Ewing sarcoma and other round cell sarcomas as follows. For the purposes of eligibility, the following pathology diagnoses are eligible and molecular confirmation is not required to enroll:
* Histologically confirmed Ewing sarcoma
* Suspected Ewing sarcoma with molecular confirmation pending
* Suspected high grade round cell sarcomas/sarcomas with eligible molecular alterations, pending molecular confirmation
* Round cell sarcoma consistent with Ewing sarcoma
* Round cell sarcoma not otherwise specified
* Round cell sarcoma
* Round cell sarcomas with EWSR1-non-ETS fusion
* CIC-rearranged sarcoma
* Sarcoma with BCOR genetic alterations
* Patients with the following pathologic diagnoses that are known to contain EWSR1 or FUS fusions are not eligible:
* Angiomatoid fibrous histiocytoma
* Extraskeletal myxoid chondrosarcoma
* Desmoplastic small round cell tumor
* Clear cell sarcoma
* Myxoid liposarcoma
* If clinical molecular testing that reports both fusion partners has been successfully completed by the site prior to enrollment, patients may only enroll if that testing reported one of the eligible fusions
* All patients must have evidence of distant metastatic disease. Biopsy of metastatic sites is not required. For this study, distant metastatic disease is defined as one or more of the following:
* Lesions which are discontinuous from the primary tumor, are not regional lymph nodes, and do not share a bone or body cavity with the primary tumor. Skip lesions in the same bone as the primary tumor do not constitute metastatic disease. Skip lesions in an adjacent bone are considered bone metastasis. If there is any doubt whether lesions are metastatic, a biopsy of those lesions should be performed
* Contralateral pleural effusion and/or contralateral pleural nodules
* Distant lymph node involvement
* Patients with pulmonary nodules are considered to have metastatic disease if the patient has:
* Solitary nodule ≥ 0.5 cm or multiple nodules of ≥ 0.3 cm unless lesion is biopsied and negative for tumor
* Patients with solitary nodule \< 0.5 cm or multiple nodules \< 0.3 cm are not considered to have lung metastasis unless biopsy documents tumor
* Bone marrow metastatic disease (bone marrow disease) is based on morphologic evidence of Ewing sarcoma based on hematoxylin and eosin (H\&E) stains. In the absence of morphologic evidence of marrow involvement on H\&E, patients with bone marrow involvement detected ONLY by flow cytometry, reverse transcriptase-polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH), immunohistochemistry or PET-CT will NOT be considered to have clinical bone marrow involvement for the purposes of this study
* Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 50 mL/min/1.73 m\^2 or serum creatinine based on age/sex as follows:
* Age: 1 to \< 2 years: Male 0.6; female 0.6
* Age: 2 to \< 6 years: Male 0.8; female 0.8
* Age: 6 to \< 10 years: Male 1; female 1
* Age: 10 to \< 13 years: Male 1.2; female 1.2
* Age: 13 to \< 16 years: Male 1.5; female 1.4
* Age: ≥ 16 years: Male 1.7; female 1.4 OR
* A 24-hour urine creatinine clearance ≥ 50 mL/min/1.73 m\^2 OR
* A GFR ≥ 50 mL/min/1.73 m\^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard)
* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age
* Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase \[ALT\]) ≤ 3 x ULN for age (except for patients with liver metastasis who may enroll if ALT ≤ 5 times ULN for age)
* Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
* Shortening fraction of ≥ 27% by echocardiogram, or ejection fraction of ≥ 50% by echocardiogram
* No known congenital QT syndrome
* No known family history of congenital QT syndrome
* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better
* Known HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
Exclusion Criteria
* Patients with regional node involvement as their only site of disease beyond the primary tumor
* Patients whose primary tumors arise in the intra-dural soft tissue (e.g., brain and spinal cord)
* Note: metastatic disease is allowable
* Patients with known Charcot-Marie-Tooth disease
* Patients who have had complete or partial resection of the primary tumor at initial diagnosis will only be eligible if adequate imaging (CT or MRI for most primary tumor sites) was obtained prior to surgery
* Patients who have received prior chemotherapy for current diagnosis, except for patients who have started cycle 1 VDC post-consent and within the timelines allowed for
* Patients who have received prior radiation therapy for current diagnosis
* Patients previously treated with a multitargeted tyrosine kinase inhibitor
* History of organ allograft (including allogeneic bone marrow transplant)
* Known hypersensitivity to regorafenib
* Active or chronic hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy
* Patients receiving strong CYP3A4 inducers or strong CYP3A4 inhibitors
* Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
* Lactating females who plan to breastfeed their infants
* Females of childbearing potential must agree to either practice medically accepted highly-effective methods of contraception or abstain from heterosexual intercourse for the duration of the protocol therapy through 12 months after the last dose of cyclophosphamide or ifosfamide, 6 months after the last dose of doxorubicin, etoposide, and irinotecan, and 7 months after the last dose of regorafenib, whichever is longer
* Male patients with female partners of childbearing potential must agree to either practice a medically accepted highly-effective methods of contraception or abstain from heterosexual intercourse for the duration of the protocol therapy through 6 months after the last dose of doxorubicin and ifosfamide, 4 months after the last dose of cyclophosphamide, etoposide and regorafenib, and 3 months after the last dose of irinotecan, whichever is longer
* All patients and/or their parents or legal guardians must sign a written informed consent
* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
* Patients whose primary tumors arise in the intra-dural soft tissue (e.g., brain and spinal cord)
* Note: metastatic disease is allowable
* Patients with known Charcot-Marie-Tooth disease
* Patients who have had complete or partial resection of the primary tumor at initial diagnosis will only be eligible if adequate imaging (CT or MRI for most primary tumor sites) was obtained prior to surgery
* Patients who have received prior chemotherapy for current diagnosis, except for patients who have started cycle 1 VDC post-consent and within the timelines allowed for
* Patients who have received prior radiation therapy for current diagnosis
* Patients previously treated with a multitargeted tyrosine kinase inhibitor
* History of organ allograft (including allogeneic bone marrow transplant)
* Known hypersensitivity to regorafenib
* Active or chronic hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy
* Patients receiving strong CYP3A4 inducers or strong CYP3A4 inhibitors
* Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
* Lactating females who plan to breastfeed their infants
* Females of childbearing potential must agree to either practice medically accepted highly-effective methods of contraception or abstain from heterosexual intercourse for the duration of the protocol therapy through 12 months after the last dose of cyclophosphamide or ifosfamide, 6 months after the last dose of doxorubicin, etoposide, and irinotecan, and 7 months after the last dose of regorafenib, whichever is longer
* Male patients with female partners of childbearing potential must agree to either practice a medically accepted highly-effective methods of contraception or abstain from heterosexual intercourse for the duration of the protocol therapy through 6 months after the last dose of doxorubicin and ifosfamide, 4 months after the last dose of cyclophosphamide, etoposide and regorafenib, and 3 months after the last dose of irinotecan, whichever is longer
* All patients and/or their parents or legal guardians must sign a written informed consent
* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Minimum Eligible Age
12 Years
Maximum Eligible Age
50 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's Oncology Group
NETWORK
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bhuvana A Setty
Role: PRINCIPAL_INVESTIGATOR
Children's Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, United States
Site Status
RECRUITING
Lurie Children's Hospital-Chicago
Chicago, Illinois, United States
Site Status
RECRUITING
NYU Langone Hospital - Long Island
Mineola, New York, United States
Site Status
RECRUITING
Saint Christopher's Hospital for Children
Philadelphia, Pennsylvania, United States
Site Status
RECRUITING
East Tennessee Childrens Hospital
Knoxville, Tennessee, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site Public Contact
Role: primary
Site Public Contact
Role: primary
Site Public Contact
Role: primary
Site Public Contact
Role: primary
Site Public Contact
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2025-00801
Identifier Type: REGISTRY
Identifier Source: secondary_id
AEWS2431
Identifier Type: OTHER
Identifier Source: secondary_id
AEWS2431
Identifier Type: OTHER
Identifier Source: secondary_id
AEWS2431
Identifier Type: -
Identifier Source: org_study_id